4SC AG ROCE
Quel est le ROCE de 4SC AG?
Le ROCE de 4SC AG est -49.47%
Quelle est la définition de ROCE?
Le retour sur capital utilisé (ROCE) est un ratio financier qui mesure la rentabilité d'une entreprise et l'efficacité avec laquelle son capital est utilisé.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE des entreprises dans Health Care secteur sur XETRA par rapport à 4SC AG
Que fait 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Entreprises avec roce similaire à 4SC AG
- Unilock Capital a ROCE de -49.86%
- DSS Inc a ROCE de -49.79%
- Genasys Inc a ROCE de -49.78%
- Hookipa Pharma Inc a ROCE de -49.72%
- Choom a ROCE de -49.69%
- ANGLE Plc a ROCE de -49.52%
- 4SC AG a ROCE de -49.47%
- Beyond Meat Inc a ROCE de -49.46%
- ProMIS Neurosciences a ROCE de -49.45%
- Shineco Inc a ROCE de -49.44%
- Calliditas Therapeutics AB (publ) a ROCE de -49.42%
- AUX Resources a ROCE de -49.38%
- Argenica Therapeutics a ROCE de -49.26%